Research and Markets: the Global Structure of Colorectal Cancer R&D; 80% of New Colon Cancer Cases Are Diagnosed in People Who Would Not Be Identified as Being at High Risk.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com) has announced the addition of The Global Structure of Colorectal Cancer colorectal cancer Malignant tumour of the large intestine (colon) or rectum. Risk factors include age (after age 50), family history of colorectal cancer, chronic inflammatory bowel diseases, benign polyps, physical inactivity, and a diet high in fat. R&D to their offering. In Europe and the US there are close to 20 million people that live with cancer today, a figure that is increasing. 6.2 million people worldwide died of cancer in 1998. The American Cancer Society American Cancer Society, n.pr established in 1913, this national volunteer-based health organization is committed to the elimination of cancer through prevention and treatment and to diminishing cancer suffering through advocacy, scholarship, research, estimates that approximately 1.2 million new cancer cases were diagnosed in the year 2000 in the US. Overall annual costs associated with cancer currently amount to $107 billion in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. alone. The worldwide anti-cancer market was valued at more than $15 billion in 1998 and is projected to nearly double by 2003. Approximately 30% of all collaborative deals are signed in the field of cancer. For colon cancer colon cancer, cancer of any part of the colon (often called the large intestine). Colon cancer is the second most common cancer diagnosed in the United States. , as for many other types of cancer, the most common treatments of today are surgery, chemotherapy and radiation therapy. Surgery is the primary form of treatment and can cure approximately 50% of the patients. Despite important advances in understanding the molecular basis of cancer, few treatments have been devised which target the known defects in tumor cells. Standard chemotherapy or radiation treatments are inherently non-selective and kill normal cells along with malignant ones. The future will be finding drugs that target specific abnormalities in specific tumor cells. Promising new drug classes under development for treatment of colorectal cancer include monoclonal antibodies This is a list of monoclonal antibodies, antibodies which are clones of a single parent cell. When used as medications, the generic names end in -mab (see "Nomenclature of monoclonal antibodies"). and angiogenesis inhibitors. Together, these newer drugs are expected to reach $337 million in annual sales by 2007. The risk for colon cancer rises substantially at the age of 50, but every year there are numerous cases in younger people. Individuals with a personal or family history of colon cancer or polyps Polyps A tumor with a small flap that attaches itself to the wall of various vascular organs such as the nose, uterus and rectum. Polyps bleed easily, and if they are suspected to be cancerous they should be surgically removed. , inherited colon cancer syndromes (i.e., FAP (language) FAP - The assembly language for Sperry-Rand 1103 and 1103A. [Listed in CACM 2(5):16 (May 1959)]. and Hnpcc), and patients with ulcerative colitis ulcerative colitis Inflammation of the colon, especially of its mucous membranes. The inflamed membranes develop patches of tiny ulcers, and the diarrhea contains blood and mucus. or Crohn's disease Crohn's disease: see colitis. are at higher risk. However, about 80% of new colon cancer cases are diagnosed in people who would not be identified as being at high risk. Only in the US, an estimated 140,000 new cases of colorectal cancer will be diagnosed in 2002. This amounts to 1 in 20 who will develop colorectal cancer during his or her life. Nevertheless, there are ways to reduce the risk of getting this disease. Screening can find pre-cancerous growths called polyps and can be removed before developing into cancer. When discovered early by existing screening tests, colorectal cancer is highly treatable. The Global Structure of Colon Cancer R&D is one of the most comprehensive and up to date information sources currently available in the colon cancer R&D arena. Information about new innovative cancer therapies such as antisense antisense, DNA or RNA manipulated in a laboratory so that its components (nucleotides) form a complementary copy of normal, or "sense," messenger RNA (mRNA; see nucleic acid). , monoclonal antibodies, gene therapy, antigen- or cellular-based vaccines, liposomal hormones and apoptotic drugs are analyzed in more than 100 extensive tables and graphs. This report will give easy-to-read tables with projects classified into well-defined structures based on type of therapy given, effect and mechanism. The graphs provide all the relations of these factors as well as the general and specific trends in the current colon cancer pipeline. Included in this 250+ page report: - Information on more than 150 companies active in colon cancer R&D - Information on more than 300 industry related colon cancer projects - Data from more than 190 clinical trials - Information on more than 90 pre-clinical projects - Over 80 graphs illustrating the most important relations between types of therapy, effects and mechanisms - Advanced analysis of general and specific trends in the pipeline Some of the companies analysed in this report include: 3D Pharmaceuticals, Abbott Laboratories Abbott Laboratories (NYSE: ABT) is a diversified pharmaceuticals and health care company. It has over 65,000 employees and operates in 130 countries. The corporate headquarters are in Abbott Park, Illinois, a neighborhood of North Chicago, Illinois. , Abgenix, Immunex, Access Oncology, AltaRex, Asta Medica medica (māˑ·dē·k , AstraZeneca, Aventis, AVI BioPharma AVI BioPharma Inc. is a medical research and drug development company with corporate offices in Portland, Oregon, United States, and laboratories in Corvallis, Oregon. It was incorporated in 1980. , Bayer, Bioenvision, Biogen, Bioniche Life Sciences, BioStratum, BioVex, BresaGen, Bristol-Myers Squibb Bristol-Myers Squibb (NYSE: BMY), colloquially referred to as BMS, is a pharmaceutical corporation, formed by a 1989 merger between pharmaceutical companies Bristol-Myers Company, founded in 1887 by William McLaren Bristol and John Ripley Myers in Clinton, NY (both were , Chiron, Corixa, Cryo-cell, Cyclacel, Eli Lilly, Epimmune, GemVax, Genentech, GlaxoSmithKline, Human Genome Sciences Human Genome Sciences NASDAQ: HGSI is a biopharmaceutical corporation founded in 1992. Its stated purpose is to "discover, develop, manufacture and market innovative drugs that serve patients with unmet medical needs, with a primary focus on protein and antibody drugs. , Igeneon, Ilex Oncology, Immune Response immune response n. An integrated bodily response to an antigen, especially one mediated by lymphocytes and involving recognition of antigens by specific antibodies or previously sensitized lymphocytes. , Immuno-Designed Molecules, Immunomedics, Imotep, Inapharma, Intracel, Isis Pharmaceuticals, Ivy Medical Chemicals, Johnson and Johnson, Kirin Brewery, Kosan, KuDOS, Kyowa Hakko, Maxygen, MedImmue, Meditech Research, Merck, Micromet, Millenium Pharmaceuticals, ML Laboratories, Mologen Holding, NeoPharm, NeoRx, Novartis, Onyx Sharma, OSI Pharmaceuticals, OXiGene, Pfizer, Pharmacia, Protarga, Roche, Sanofi-Synthelabo, Schering AG, Schering-Plough, Serono, Shionogi, Sirna Therapeutics, SuperGen, Taisho Pharma, Telik, Titan Pharmaceuticals, Tularik, Wyeth, Xenova, YM Biosciences. The Global Structure of Colon Cancer R&D is an excellent source of information providing a solid presentation of exciting and rapidly evolving therapeutics and enabling companies to establish potential partners and competitors. This report will assist in: - Tracking cutting edge companies, therapies and new technologies - Rapid identification of partners and competitors - Laying down a comprehensive framework for further analysis of the field - Producing presentations surrounding the development of colon cancer therapeutics - Identifying emerging colon cancer products and key areas of pharmaceutical R&D Report Contents: Table of Contents EXECUTIVE SUMMARY METHODOLOGY AND DESCRIPTIONS INTRODUCTION INFORMATION STRUCTURES INFORMATION ANALYSIS - Summaries - Therapeutic Effect - Effect in Relation to Stage - Stage in Relation to Effect - Therapy Given in Relation to Stage - Stage in Relation to Therapy Given - Mechanism in Relation to Effect - Effect in Relation to Mechanism - Mechanism in Relation to Therapy Given - Therapy Given in Relation to Mechanism - Therapy Given in Relation to Effect - Effect in Relation to Therapy Given - General Clinical Pipeline Trends - Clinical Pipeline Trends Divided by Effect - Clinical Pipeline Trends Divided by Therapy Given - Other Clinical Pipeline Trends - Early vs. Late Stage Pipeline R&D Trends - Order Information For more information visit http://www.researchandmarkets.com/reports/c2788 |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion